New anticoagulants for atrial fibrillation

Seminars in Thrombosis and Hemostasis

Volumn 35, Issue 5, 2009, Pages 515-524

  Sobieraj Teague, Magdalena ^a   Odonnell, Martin ^a   Eikelboom, John ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Anticoagulants; Atrial fibrillation; Direct thrombin inhibitor; Factor Xa inhibitor; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; ATI 5923; AZD 0837; BETRIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING INHIBITOR; CLARITHROMYCIN; CYTOCHROME P450 3A4; DABIGATRAN ETEXILATE; DU 176B; GLYCOPROTEIN P INHIBITOR; HEPARIN; IDRABIOTAPARINUX; IDRAPARINUX; KETOCONAZOLE; QUINIDINE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RITONAVIR; RIVAROXABAN; UNCLASSIFIED DRUG; VORICONAZOLE; WARFARIN; XIMELAGATRAN; YM 150;

BLEEDING; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DESIGN; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEART ATRIUM FIBRILLATION; HUMAN; KIDNEY DYSFUNCTION; LIVER TOXICITY; LONG TERM CARE; LOW DRUG DOSE; LUNG EMBOLISM; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW; RISK FACTOR; STROKE; THROMBOSIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZAMIDES; BENZIMIDAZOLES; BIOTIN; CLINICAL TRIALS, PHASE III AS TOPIC; FACTOR XA; HUMANS; MORPHOLINES; OLIGOSACCHARIDES; PYRAZOLES; PYRIDINES; PYRIDONES; THIAZOLES; THIOPHENES; VITAMIN K;

EID: 70350254762     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0029-1234147     Document Type: Review

References (49)

1. Go A S., Hylek E M., Phillips K A. et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001 285 (18) 2370-2375
2. Miyasaka Y, Barnes M E., Gersh B J. et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006 114 (2) 119-125
3. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994 154 (13) 1449-1457
4. Wolf P A., Abbott R D., Kannel W B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991 22 (8) 983-988
5. Dulli D A., Stanko H, Levine R L. Atrial fibrillation is associated with severe acute ischemic stroke. Neuroepidemiology 2003 22 (2) 118-123
6. Lin H J., Wolf P A., Kelly-Hayes M et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke 1996 27 (10) 1760-1764
7. Wolf P A., Mitchell J B., Baker C S., Kannel W B., DAgostino R B. Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med 1998 158 (3) 229-234
8. Hart R G., Pearce L A., Aguilar M I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007 146 (12) 857-867
9. Lip G Y., Edwards S J. Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis. Thromb Res 2006 118 (3) 321-333
10. Glazer N L., Dublin S, Smith N L. et al. Newly detected atrial fibrillation and compliance with antithrombotic guidelines. Arch Intern Med 2007 167 (3) 246-252
11. Hart R G., Benavente O, McBride R, Pearce L A. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999 131 (7) 492-501
12. Albers G W., Dalen J E., Laupacis A, Manning W J., Petersen P, Singer D E. Antithrombotic therapy in atrial fibrillation. Chest 2001 119 (1, suppl) 194S-206S
13. Go A S., Hylek E M., Borowsky L H., Phillips K A., Selby J V., Singer D E. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med 1999 131 (12) 927-934
14. Go A S., Hylek E M., Chang Y et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA 2003 290 (20) 2685-2692
15. McCormick D, Gurwitz J H., Goldberg R J. et al. Prevalence and quality of warfarin use for patients with atrial fibrillation in the long-term care setting. Arch Intern Med 2001 161 (20) 2458-2463
16. Bradley B C., Perdue K S., Tisdel K A., Gilligan D M. Frequency of anticoagulation for atrial fibrillation and reasons for its non-use at a Veterans Affairs medical center. Am J Cardiol 2000 85 (5) 568-572
17. Bungard T J., Ghali W A., Teo K K., McAlister F A., Tsuyuki R T. Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med 2000 160 (1) 41-46
18. Jones M, McEwan P, Morgan C L., Peters J R., Goodfellow J, Currie C J. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population. Heart 2005 91 (4) 472-477
19. Rose A J., Ozonoff A, Henault L E., Hylek E M. Warfarin for atrial fibrillation in community-based practise. J Thromb Haemost 2008 6 (10) 1647-1654
20. Shalev V, Rogowski O, Shimron O et al. The interval between prothrombin time tests and the quality of oral anticoagulants treatment in patients with chronic atrial fibrillation. Thromb Res 2007 120 (2) 201-206
21. Hylek E M., Go A S., Chang Y et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003 349 (11) 1019-1026
22. White H D., Gruber M, Feyzi J et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med 2007 167 (3) 239-245
23. Wienen W, Stassen J M., Priepke H, Ries U J., Hauel N. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost 2007 98 (1) 155-162 (Pubitemid 47078782)
24. Stangier J, Rathgen K, Stähle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007 64 (3) 292-303
25. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008 47 (5) 285-295
26. Sanford M, Plosker G L. Dabigatran etexilate. Drugs 2008 68 (12) 1699-1709
27. Eriksson B I., Dahl O E., Rosencher N et al, RE-MODEL Study Group. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007 5 (11) 2178-2185 (Pubitemid 47617868)
28. Eriksson B I., Dahl O E., Rosencher N et al, RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007 370 (9591) 949-956 (Pubitemid 47393577)
29. Ginsberg J S., Davidson B L., Comp P C. et al, RE-MOBILIZE Writing Committee. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009 24 (1) 1-9
30. Ezekowitz M D., Reilly P A., Nehmiz G et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol 2007 100 (9) 1419-1426
31. Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939an oral, direct Factor Xa inhibitorafter multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005 61 (12) 873-880
32. Weinz C, Schwartz T, Pleiss U. Metabolism and distribution of (14C) BAY 59-7939an oral, direct factor Xa inhibitorin rat, dog and human [abstract 196]. Drug Metab Rev 2004 36 (suppl 1)
33. Eriksson B I., Quinlan D J., Weitz J I. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin Pharmacokinet 2009 48 (1) 1-22
34. Kakkar A K., Brenner B, Dahl O E. et al, RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008 372 (9632) 31-39
35. Eriksson B I., Borris L C., Friedman R J. et al, RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008 358 (26) 2765-2775
36. Lassen M R., Ageno W, Borris L C. et al, RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008 358 (26) 2776-2786
37. Turpie A, Bauer K, Davidson B et al. Comparison of Xareltoan oral, direct factor Xa inhibitor and subcutaneous enoxaparin for thromboprophylaxis after total knee replacement (RECORD4: a phase 3 study). Paper presented at: European Federation of National Associations of Orthopaedics and Traumatology annual meeting May 29June 1, 2008 Nice, France Abstract F85
38. Frost C, Yu Z, Nepal S. Apixaban, a direct factor Xa inhibitor: single-dose pharmacokinetics and pharmacodynamics of an intravenous formulation. Paper presented at: 37th American College of Chest Physicians annual meeting September 1416, 2008 Philadelphia, PA
39. Raghavan N, Frost C E., Yu Z et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 2009 37 (1) 74-81
40. Lassen M R., Davidson B L., Gallus A, Pineo G, Ansell J, Deitchman D. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 2007 5 (12) 2368-2375
41. Buller H R. Late breaking clinical trial: a dose finding study of the oral direct factor xa inhibitor apixaban in the treatment of patients with acute symptomatic deep vein thrombosis The Botticelli Investigators. J Thromb Haemost 2007 5 (suppl 2) Abstract S-003
42. Zafar M U., Vorchheimer D A., Gaztanaga J et al. Antithrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber. Thromb Haemost 2007 98 (4) 883-888
43. Walenga J M., Jeske W P., Fareed J. Short- and long-acting synthetic pentasaccharides as antithrombotic agents. Expert Opin Investig Drugs 2005 14 (7) 847-858
44. Herbert J M., Hérault J P., Bernat A et al. Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. Blood 1998 91 (11) 4197-4205
45. Trellu M, Perez Y, Ortiz J, Cheng S, Paty I. Bioequipotency of idraparinux and biotinylated idraparinux after single dose in healthy subjects. [Abstract P-T-678] J Thromb Haemost 2007 5 (suppl 1) Abstract P-T-678
46. Buller H R., Destors J, Gallus A S., Prins M H., Raskob G E. Idrabiotaparinux, a biotinylated long-acting anticoagulant, in the treatment of deep venous thrombosis (EQUINOX study): safety, efficacy, and reversibility by avidin. Paper presented at: American Society of Hematology 2008 San Francisco, CA
47. Buller H R., Cohen A T., Davidson B et al, van Gogh Investigators. Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med 2007 357 (11) 1094-1104
48. Bousser M G., Bouthier J, Büller H R. et al, Amadeus Investigators. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. Lancet 2008 371 (9609) 315-321
49. Ezekowitz M D., Milner P, Ellis D et al. The utility of genotyping in the first evaluation of a novel vitamin K antagonist: ATI-5923. Circulation 2008 118 (Suppl 885) Abstract 4415